What is CircNova?
Founded in 2023, CircNova operates at the intersection of artificial intelligence and molecular biology. The company utilizes its proprietary NovaEngine to identify and analyze circular RNA, a novel class of molecules with significant potential for therapeutic intervention. By targeting disease pathways previously considered undruggable, CircNova is addressing critical gaps in clinical care. The firm's strategic focus on circular RNA provides a distinct competitive advantage, as these molecules offer enhanced stability and expression profiles compared to traditional linear RNA therapies, making them ideal candidates for complex, long-term treatment regimens.
How much funding has CircNova raised?
CircNova has raised a total of $3.3M across 1 funding round:
Angel/Seed
$3.3M
Angel/Seed (2025): $3.3M with participation from Spark Capital, South Loop Ventures, and Invest Detroit Ventures
Key Investors in CircNova
Spark Capital
A multi-stage venture capital firm known for backing high-growth technology companies across various sectors, providing founders with the resources to scale disruptive products.
South Loop Ventures
A Houston-based early-stage venture fund that prioritizes transformational ideas in healthtech and other sectors, focusing on diverse founding teams with bold, long-term visions.
Invest Detroit Ventures
A regional investment entity dedicated to fostering entrepreneurial growth and providing strategic guidance to emerging businesses navigating the complexities of corporate formation and scaling.
What's next for CircNova?
With this recent infusion of capital, CircNova is poised to accelerate its research and development pipeline. The company plans to scale its NovaEngine capabilities to broaden its therapeutic target identification, moving closer to preclinical validation for its lead candidates. As the firm transitions into a more mature phase of its lifecycle, the focus will shift toward establishing strategic partnerships with larger pharmaceutical entities and expanding its internal laboratory infrastructure. This growth trajectory is supported by a diverse group of investors who recognize the transformative potential of circular RNA in modern medicine.
See full CircNova company page
